Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03580382 · ClinicalTrials.gov registry record · Phase 1
Study of CDX-3379, a Human Monoclonal Antibody Targeting ERBB3, in Combination With the MEK Inhibitor, Trametinib, in Patients With Advanced Stage NRAS Mutant and BRAF/NRAS Wildtype (WT) Melanoma
A Phase 1 study, sponsored by NYU Langone Health.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT03580382 is a Phase 1 study that was terminated before completion, run by NYU Langone Health. The registered enrollment target is 3 participants.
The verdict
NCT03580382, a Phase 1 study, was terminated before completion, sponsored by NYU Langone Health.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
The main goal of this study is to test if it is safe and effective to give CDX-3379 together to treat advanced melanoma in patients with the NRAS mutation and BRAF/NRAS wildtype.
Interventions
- DRUG Trametinib daily Until PD
- DRUG CDX-3379 (ERBB3 antibody)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2018-07-06 |
| Est. Completion | 2018-09-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03580382
The ClinicalTrials.gov registry entry for NCT03580382 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Trametinib daily Until PD is the first listed.
NCT03580382 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03580382 about?
NCT03580382 is a clinical study titled "Study of CDX-3379, a Human Monoclonal Antibody Targeting ERBB3, in Combination With the MEK Inhibitor, Trametinib, in Patients With Advanced Stage NRAS Mutant and BRAF/NRAS Wildtype (WT) Melanoma". The main goal of this study is to test if it is safe and effective to give CDX-3379 together to treat advanced melanoma in patients with the NRAS mutation and BRAF/NRAS wildtype.
What is the current status of trial NCT03580382?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2018-07-06. Estimated completion is 2018-09-26.
What interventions are being tested in trial NCT03580382?
The interventions under investigation include: Trametinib daily Until PD (DRUG), CDX-3379 (ERBB3 antibody) (DRUG).
Who is sponsoring clinical trial NCT03580382?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.